Bio-Thera Solutions has dosed the first subject in the Phase I clinical trial of bispecific antibody, BAT7104, to treat advanced solid tumours in Australia.

BAT7104 hinders the interaction of human PD-L1 and CD47 with their respective receptors.

The multicentre, open-label, dose-escalation trial will analyse the safety and tolerability of BAT7104 to treat advanced solid tumours.

Determining the maximum tolerated dose and recommended Phase II dose (RP2D) of BAT7104 and assessing the pharmacokinetics and initial efficacy of the antibody in advanced solid tumour patients are the main goals of the trial.

BAT7104 demonstrated to hinder PD-1/PD-L1 and CD47/SIRP-α pathways in vitro and showed synergistic activity in eliciting total tumour regression in vivo. 

Bio-Thera Solutions CEO Dr Shengfeng Li said: “BAT7104 has demonstrated higher anti-tumour activity with better safety profile in preclinical studies.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As the first bispecific antibody of Bio-Thera, we are pleased to see BAT7104 enter clinical development in Australia, and we will continue bringing more innovative anti-tumour drugs to cancer patients.”

Apart from the trial in Australia, the company is carrying out a Phase I trial of BAT7104 in China enrolling solid tumour and lymphoma patients. 

Bio-Thera focuses on the development of new therapies to treat cancer, autoimmune, cardiovascular ailments and other serious unmet medical needs.

The company is also developing various new oncology assets in early-stage trials, which are directed at key IO targets, including OX40, CTLA-4, PD-1 and TIGIT.

In March this year, Bio-Thera dosed the first subject in Phase I trial of BAT6026 plus BAT1308 for the treatment of advanced solid tumour patients in Australia.